B
69.12
-1.16 (-1.65%)
| Previous Close | 70.28 |
| Open | 70.40 |
| Volume | 1,826,430 |
| Avg. Volume (3M) | 2,453,585 |
| Market Cap | 13,537,930,240 |
| Price / Sales | 22.39 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2026 |
| Operating Margin (TTM) | -89.00% |
| Diluted EPS (TTM) | -3.56 |
| Quarterly Revenue Growth (YOY) | -44.80% |
| Current Ratio (MRQ) | 4.57 |
| Operating Cash Flow (TTM) | -500.42 M |
| Levered Free Cash Flow (TTM) | -261.20 M |
| Return on Assets (TTM) | -48.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | BridgeBio Pharma, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.2
| Analyst Consensus | 4.0 |
| Insider Activity | -5.0 |
| Price Volatility | 1.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.0 |
| Average | -0.20 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 4.97% |
| % Held by Institutions | 98.14% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Kohlberg Kravis Roberts & Co. L.P. | 31 Mar 2026 | 13,260,971 |
| Aisling Capital Management Lp | 31 Mar 2026 | 5,089,611 |
| 52 Weeks Range | ||
| Median | 94.00 (36.00%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 10 Mar 2026 | 94.00 (36.00%) | Buy | 74.32 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| APULI MARICEL | - | 66.13 | -4,714 | -311,737 |
| KUMAR NEIL | - | 66.13 | -36,236 | -2,396,287 |
| SCOTT RANDAL W. | - | 66.13 | -10,000 | -661,300 |
| TRIMARCHI THOMAS | - | 65.73 | -36,432 | -2,398,191 |
| Aggregate Net Quantity | -87,382 | |||
| Aggregate Net Value ($) | -5,767,514 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 65.97 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TRIMARCHI THOMAS | Officer | 18 May 2026 | Automatic sell (-) | 13,651 | 65.32 | 891,683 |
| APULI MARICEL | Officer | 16 May 2026 | Disposed (-) | 4,714 | 66.13 | 311,737 |
| KUMAR NEIL | Officer | 16 May 2026 | Disposed (-) | 36,236 | 66.13 | 2,396,287 |
| KUMAR NEIL | Officer | 16 May 2026 | Option execute | 71,215 | - | - |
| TRIMARCHI THOMAS | Officer | 16 May 2026 | Disposed (-) | 22,781 | 66.13 | 1,506,508 |
| SCOTT RANDAL W. | Director | 15 May 2026 | Automatic sell (-) | 10,000 | 66.13 | 661,300 |
| SCOTT RANDAL W. | Director | 15 May 2026 | Option execute | 10,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |